Company Overview

Update
Founded:
1996
Headquarters:
West Lafayette, IN
IPO:
Went Public on Apr 7, 2014
Stock:
EYCT
Categories:
Health Care, Biotechnology
Description:
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases.

Detailed Description

Update

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.

Current Team (2)

Update

Board Members and Advisors (2)

Update

Investors (7)

Update

Offices/Locations (1)

Update
  • Headquarters

    3000 Kent Avenue

    Suite A1-100

    West Lafayette, IN 47906

    USA

Images (1)

Update
  • 1aa4031a5dff0433f6d598c3ca60ac64